Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NextCure, Inc.    NXTC


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

NextCure Announces Pricing of Initial Public Offering of Common Stock

share with twitter share with LinkedIn share with facebook
05/08/2019 | 08:48pm EDT

BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. NextCure’s common stock has been approved for listing and is expected to begin trading on The Nasdaq Global Select Market on May 9, 2019 under the ticker symbol “NXTC”. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, will be $75.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2019, subject to the satisfaction of customary closing conditions.

Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on May 8, 2019. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
SVP, Corporate Development
(240) 762-6486

Media Inquiries
Shai Biran, Ph.D.
(781) 235-3060

© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
Latest news on NEXTCURE, INC.
06/11NEXTCURE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/29NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Po..
05/07NEXTCURE : Management's Discussion and Analysis of Financial Condition and Resul..
05/07NextCure Reports First Quarter 2020 Financial Results
05/06NextCure to Present at BofA Securities Virtual Health Care Conference
04/14NEXTCURE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
04/13NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-..
04/08NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
03/30NEXTCURE, INC. : Change in Directors or Principal Officers, Regulation FD Disclo..
03/30NEXTCURE : Announces Appointment of Veteran Oncology Executive Garry Nicholson t..
More news
Financials (USD)
Sales 2020 23,0 M - -
Net income 2020 -34,4 M - -
Net cash 2020 292 M - -
P/E ratio 2020 -17,5x
Yield 2020 -
Capitalization 583 M 583 M -
EV / Sales 2019
EV / Sales 2020 12,6x
Nbr of Employees 69
Free-Float 86,5%
Duration : Period :
NextCure, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXTCURE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 65,88 $
Last Close Price 21,17 $
Spread / Highest target 311%
Spread / Average Target 211%
Spread / Lowest Target 88,9%
EPS Revisions
Michael S. Richman President, Chief Executive Officer & Director
David S. Kabakoff Chairman
Timothy Mayer Chief Operating Officer
Steven P. Cobourn Chief Financial Officer
Kevin N. Heller Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEXTCURE, INC.-62.42%583
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697